GGrantIndex
Sort

48,018 grants matching immunotherapy

Impact of tuberculosis on the development and function of the immune system in SIV-infected infants

$1,225,642
Xiaolei Wang · Tulane University Of Louisiana · R01 · FY2023 · HD

Impact of tuberculosis on the development and function of the immune system in SIV-infected infants

$1,225,642
Xiaolei Wang · Tulane University Of Louisiana · R01 · FY2021 · HD

Impact of tuberculosis on the development and function of the immune system in SIV-infected infants

$1,225,614
Xiaolei Wang · Tulane University Of Louisiana · R01 · FY2020 · HD

A Phase II Controlled Trial of Allogeneic Mesenchymal Stromal Cells for the Treatment of Refractory Lupus (MiSLE)

$1,225,013
Gary S. Gilkeson · Medical University Of South Carolina · U01 · FY2024 · AI

Mechanistic investigation of therapies for Down Syndrome Regression Disorder

$1,224,805
Joaquin M. Espinosa · University Of Colorado Denver · R33 · FY2025 · HD

Development of botulinum neurotoxin immunotherapy

$1,224,595
University Of California San Francisco · U01 · FY2004 · AI

Preclinical Development of a Thermostable Trivalent Filovirus Vaccine

$1,224,098
Axel T Lehrer · University Of Hawaii At Manoa · R01 · FY2018 · AI

Discovery and development of lineage-restricted pediatric cancer surfaceome immunotherapeutic targets

$1,223,848
John M Maris · Children'S Hosp Of Philadelphia · U54 · FY2018 · CA

REGULATION OF ANTI-TUMOR IMMUNITY

$1,223,793
Eckhard R Podack · University Of Miami School Of Medicine · P01 · FY2007 · CA

GENERAL CLINICAL RESEARCH CENTER

$1,223,437
University Of Texas Hlth Sci Ctr Houston · M01 · FY2000 · RR

New Jersey Pediatric AIDS Clinical Trials Consortium

$1,223,366
Univ Of Med/Dent Of Nj-Nj Medical School · U01 · FY2004 · AI

Novel Molecular Therapies of Prostate Cancer

$1,222,825
Dario C. Altieri · Wistar Institute · P01 · FY2018 · CA

IN VIVO 31P MRS STUDIES OF NON-HODGKIN'S LYMPHOMA

$1,222,597
Fernando Arias-Mendoza · Columbia University Health Sciences · R01 · FY2010 · CA

Analysis of Host-Pathogen Interactions

$1,222,253
Ronald Germain · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI

Innate inflammatory responses during pulmonary infections

$1,222,241
Katrin Mayer-Barber · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI

Therapeutic Fully Human Monoclonal Antibodies against Vaccina Virus and Smallpox

$1,221,981
Shane P Crotty · La Jolla Institute For Immunology · U01 · FY2010 · AI

Immunologic Correlates of Immunization for Cancer

$1,221,861
University Of Washington · U54 · FY2002 · CA

The connection of innate and adaptive anti-cancer immunity

$1,221,774
John Greiner · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA

A platform for T-cell receptor mimic antibody generation modeled using pHLA-A*11:01 KRAS G12D

$1,221,746
Michael P Weiner · Precision Biotools Inc · R44 · FY2025 · GM

Preclinical toxicology and pharmacology evaluation of a newTNFR2 antagonistic monoclonal antibody for CTCL therapy

$1,221,684
Kenneth Olivier · Boston Immune Technologies And Therapeutics, Inc. · R44 · FY2023 · CA

TissueReM: Whole-Organism, Real-time Decision-enabled 3D Tissue Imaging and Recovery for Molecular Analysis

$1,221,189
Madhusudhana Gargesha · Bioinvision, Inc. · R44 · FY2025 · GM

Rational Approaches to Melanoma Therapy

$1,220,153
Jessie Villanueva · Wistar Institute · U54 · FY2024 · CA

Rapid response for pandemics: single cell sequencing and deep learning to predict antibody sequences against an emerging antigen

$1,219,945
Animesh Ray · Keck Graduate Inst Of Applied Life Scis · R01 · FY2023 · AI

Development of polymeric synthetic biomaterial IP-001 to potentiate asystemic immunotherapy of hepatocellular carcinoma via thermal ablation

$1,219,852
Siu Kit Lam · Immunophotonics, Inc. · R44 · FY2023 · CA

Multi-OMICS identification and validation of mechanisms triggered by Immune interventions aimed at reducing the size of the replication competent Reservoir

$1,219,661
Rafick-Pierre Sekaly · Emory University · P01 · FY2024 · AI